Condition: Stargardt Disease · Cone Rod Dystrophy · Juvenile Macular Degeneration · Sponsor: Ascidian Therapeutics, Inc
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
This description comes directly from the study's public registry record.
Associate Director, Clinical Operations · 207-573-0412 · researchtrials@ascidian-tx.com
Always discuss trial participation with your own doctor first.
| University of San Francisco | San Francisco, California, United States | Recruiting |
| Vitreo Retinal Associates | Gainesville, Florida, United States | Recruiting |
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| Wilmer Eye Institute at John Hopkins | Baltimore, Maryland, United States | Recruiting |
| Massachusetts Eye and Ear | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Kellogg Eye Center | Ann Arbor, Michigan, United States | Recruiting |
| Cincinnati Eye Institute | Cincinnati, Ohio, United States | Recruiting |
| Casey Eye Institute OHSU | Portland, Oregon, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| Retina Consultants of Texas | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06467344